Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 20/20 | 0.82 |
| ▸ | MTOR | P42345 | 20/20 | 0.82 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.82 |
| ▸ | PIK3CG | P48736 | 15/20 | 0.81 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.81 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.81 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.81 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24709929 | 0.94 | PIK3CA (0.85) | PIK3CAMTORPIK3R1PIK3CGPIK3CB | |
| SCHEMBL32187 | 0.91 | PIK3CA (0.86) | PIK3CAMTORPIK3R1PIK3CGPIK3CB | |
| SCHEMBL17677805 | 0.90 | PIK3CA (1.00) | PIK3CAMTORPIK3R1PIK3CGPIK3CB | |
| SCHEMBL22193415 | 0.90 | PIK3CA (0.82) | PIK3CAMTORPIK3R1PIK3CGPIK3CB | |
| Gedatolisib SCHEMBL32393 | 0.89 | MTOR (1.00) | PIK3CAMTORPIK3R1PIK3CGPIK3CB | |
| Gedatolisib SCHEMBL20765097 | 0.89 | MTOR (1.00) | PIK3CAMTORPIK3R1PIK3CGPIK3CB | |
| SCHEMBL32568 | 0.89 | PIK3CA (0.93) | PIK3CAMTORPIK3R1PIK3CGPIK3CB | |
| SCHEMBL32186 | 0.88 | PIK3CA (1.00) | PIK3CAMTORPIK3R1PIK3CGPIK3CB | |
| SCHEMBL32259 | 0.88 | PIK3CA (0.81) | PIK3CAMTORPIK3R1PIK3CGPIK3CB | |
| SCHEMBL26835992 | 0.88 | PIK3CA (0.82) | PIK3CAMTORPIK3R1PIK3CGPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11813334-B2 | Polyethylene glycol conjugate drug, and preparation method therefor and use thereof | Chongqing Upgra Biotechnology Co., Ltd. (CN) | 2023-11-14 | — | — | US | disclosed |
| US-20160002222-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2016-01-07 | — | — | US | disclosed |
| US-9073916-B2 | Prodrug forms of kinase inhibitors and their use in therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2015-07-07 | — | — | US | disclosed |
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | NTRK3, TK1, TNNI3K | PIK3CA 87/4885MTOR 414/4885PIK3R1 144/4885 |
| US-11813334-B2 | Polyethylene glycol conjugate drug, and preparation method therefor and use thereof | FAR1, SLC10A1, THEM6 | PIK3CA 1905/4885MTOR 2989/4885PIK3R1 1923/4885 |
| US-20160002222-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | NTRK3, TK1, TNNI3K | PIK3CA 106/4885MTOR 460/4885PIK3R1 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.